From 1989 to 2003, 709 phase III trials evaluating systemic cancer treatment were presented at ASCO meetings. Tam and collaborators have now reported that 9% of these trials were never published, and 13% were published after a 5-year delay. More than half of these studies would have had clinical impact if published promptly.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Smith, R. Classical peer review: an empty gun. Breast Cancer Res. 12 (Suppl. 4), S13 (2010).
Tam, V. C., Tannock, I. F., Massey, C., Rauw, J. & Krzyzanowska, M. K. Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice. J. Clin. Oncol. 29, 3133–3139 (2011).
Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
Joensuu, H. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809–820 (2006).
Love, N. (Ed.) Patterns of care in medical oncology—Breast cancer edition. Vol. 1 (Research to Practice, Miami, 2005).
Love, N. (Ed.) Patterns of care in medical oncology—Breast cancer edition. Vol. 2 (Research to Practice, Miami, 2005).
Lefebvre, C., Manheimer, E. & Glanville, J. in Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (eds Higgins, J. P. T. & Green, S.) Ch. 6 (The Cochrane Collaboration[online], 2011).
[No authors listed] Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 365, 1687–1717 (2005).
Andre, F. et al. Biomarker studies: a call for a comprehensive biomarker study registry. Nat. Rev. Clin. Oncol. 8, 171–176 (2011).
Acknowledgements
Supported in part by a grant from the Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale™.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
D. F. Hayes declares he is a consultant for Biomarker Strategies and Chugai Pharmaceuticals and he receives research funding from Novartis, Pfizer and Veridex LLC. He also owns shares from Oncimmune. He has two pending patents regarding the use and development of assays for circulating tumor cells.
Rights and permissions
About this article
Cite this article
Hayes, D. The silent minority—unpublished data on cancer care. Nat Rev Clin Oncol 8, 631–632 (2011). https://doi.org/10.1038/nrclinonc.2011.148
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.148
